Literature DB >> 3036709

Nonoxidative microbicidal activity in normal human alveolar and peritoneal macrophages.

J R Catterall, C M Black, J P Leventhal, N W Rizk, J S Wachtel, J S Remington.   

Abstract

Although Toxoplasma gondii multiplies within normal murine alveolar and peritoneal macrophages, it is killed by normal rat alveolar and peritoneal macrophages. The killing by rat macrophages is by a nonoxidative mechanism. Studies on normal human alveolar macrophages have reported disparate results in regard to their ability to inhibit or kill T. gondii. We considered it of interest to explore further the effect of normal human alveolar and peritoneal macrophages on T. gondii. Unstimulated alveolar macrophages from each of seven individuals demonstrated a marked ability to kill or inhibit multiplication of T. gondii in vitro (e.g., the number of parasites per 100 alveolar macrophages was 31 at time zero and 2 at 18 h, whereas this value increased from 37 at time zero to 183 at 18 h in murine macrophages assayed in parallel). In quantitative assays of superoxide, alveolar macrophages released a substantial amount of superoxide when exposed to phorbol myristate acetate or to candidae. In contrast, alveolar macrophages incubated with T. gondii released no more superoxide than when in medium alone. Scavengers of superoxide anions, hydrogen peroxide, singlet oxygen, and hydroxyl radicals failed to inhibit killing of T. gondii by alveolar macrophages. Peritoneal macrophages from each of six normal women undergoing laparoscopy killed T. gondii in vitro; results of quantitative superoxide assays and scavenger experiments demonstrated that no oxidative burst was triggered in these macrophages by exposure to T. gondii. These data indicate that normal human alveolar and peritoneal macrophages can kill an intracellular parasite by nonoxidative mechanisms and suggest that these mechanisms are important in inhibition or killing of other opportunistic intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036709      PMCID: PMC260570          DOI: 10.1128/iai.55.7.1635-1640.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Toxoplasmosis complicating malignancy. Experience at the National Cancer Institute.

Authors:  W M Vietzke; A H Gelderman; P M Grimley; M P Valsamis
Journal:  Cancer       Date:  1968-05       Impact factor: 6.860

Review 2.  Mechanisms of macrophage antimicrobial activity.

Authors:  C F Nathan
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

3.  Killing capacity of human polymorphonuclear leukocytes in aerobic and anaerobic conditions.

Authors:  W A Vel; F Namavar; A M Verweij; A N Pubben; D M MacLaren
Journal:  J Med Microbiol       Date:  1984-10       Impact factor: 2.472

4.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage.

Authors:  G W Hunninghake; J E Gadek; O Kawanami; V J Ferrans; R G Crystal
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

5.  Mechanisms of killing of Toxoplasma gondii by rat peritoneal macrophages.

Authors:  R E McCabe; J S Remington
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Bactericidal activity of fractionated granule contents from human polymorphonuclear leukocytes: antagonism of granule cationic proteins by lipopolysaccharide.

Authors:  M C Modrzakowski; J K Spitznagel
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

7.  Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma.

Authors:  H W Murray; R A Gellene; D M Libby; C D Rothermel; B Y Rubin
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Defensins. Natural peptide antibiotics of human neutrophils.

Authors:  T Ganz; M E Selsted; D Szklarek; S S Harwig; K Daher; D F Bainton; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Alveolar macrophage dysfunction in human bone marrow transplant recipients.

Authors:  D J Winston; M C Territo; W G Ho; M J Miller; R P Gale; D W Golde
Journal:  Am J Med       Date:  1982-12       Impact factor: 4.965

10.  The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

Authors:  H Masur; T C Jones
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  10 in total

1.  Differences in microbicidal activities of human macrophages against Toxoplasma gondii and Trypanosoma cruzi.

Authors:  D M Israelski; F G Araujo; J S Wachtel; L Heinrichs; J S Remington
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

2.  Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity.

Authors:  J R Perfect; M M Hobbs; D L Granger; D T Durack
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

3.  In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B.

Authors:  J E Wolf; S E Massof
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

4.  Trypanosoma cruzi but not Trypanosoma brucei fails to induce a chemiluminescent signal in a macrophage hybridoma cell line.

Authors:  B Vray; P De Baetselier; A Ouaissi; Y Carlier
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

5.  Acquired immunity in experimental murine aspergillosis is mediated by macrophages.

Authors:  L de Repentigny; S Petitbois; M Boushira; E Michaliszyn; S Sénéchal; N Gendron; S Montplaisir
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

Review 6.  Fc gamma receptors in cancer and infectious disease.

Authors:  M W Fanger; D V Erbe
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 7.  Role of gamma interferon in Toxoplasma gondii infection.

Authors:  C S Subauste; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

8.  Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii.

Authors:  T M Scharton-Kersten; G Yap; J Magram; A Sher
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

9.  Pre- and peri-implantation Zika virus infection impairs fetal development by targeting trophectoderm cells.

Authors:  Lei Tan; Lauretta A Lacko; Ting Zhou; Delia Tomoiaga; Romulo Hurtado; Tuo Zhang; Ana Sevilla; Aaron Zhong; Christopher E Mason; Scott Noggle; Todd Evans; Heidi Stuhlmann; Robert E Schwartz; Shuibing Chen
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

10.  Lower expression of inducible nitric oxide synthase and higher expression of arginase in rat alveolar macrophages are linked to their susceptibility to Toxoplasma gondii infection.

Authors:  Zhi-Jun Zhao; Jia Zhang; Jun Wei; Zhi Li; Tao Wang; Si-Qi Yi; Ji-Long Shen; Ting-Bao Yang; Geoff Hide; Zhao-Rong Lun
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.